Enzyme News and Research

RSS

Pupil can constrict without any input from brain

You've seen it on television: A doctor shines a bright light into an unconscious patient's eye to check for brain death. If the pupil constricts, the brain is OK, because in mammals, the brain controls the pupil. Or does it? Now, researchers at Johns Hopkins have discovered that in most mammals, in fact in most vertebrates, the pupil can constrict without any input from the brain.

3 Nov 2011

Researchers discover key enzymes that are critical for sperm function

Compared to most other cells in an organism, sperm undergo a radical transformation to become compact and mobile delivery systems for paternal DNA. Even though sperm looks and moves quite differently across species, SF State researcher Diana Chu and colleagues now say that there are at least a few key enzymes that are critical for sperm development and mobility in species as different as mice and nematode worms.

2 Nov 2011

Health risk associated with harmful substances in food may be underestimated

Mice are often used to test whether substances in food are harmful to humans. This requires that mice and humans metabolise substances in the same way. Humans have certain enzymes in more parts of the body than mice. The health risk associated with harmful substances in food may therefore be underestimated.

2 Nov 2011

Peroxiredoxin enzyme holds key to ageing process

By consuming fewer calories, ageing can be slowed down and the development of age-related diseases such as cancer and type 2 diabetes can be delayed. The earlier calorie intake is reduced, the greater the effect. Researchers at the University of Gothenburg have now identified one of the enzymes that hold the key to the ageing process.

1 Nov 2011

Leg muscle dysfunction related to severity of symptoms in heart failure patients

Doctors should not only treat the heart muscle in chronic heart failure patients, but also their leg muscles through exercise, say researchers in a study published today in the Journal of Applied Physiology.

31 Oct 2011

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced that it has initiated two Phase 1 clinical trials of IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. These two enzymes are implicated in hematologic cancers as well as a broad range of inflammatory conditions, which are the areas of focus within Infinity's PI3K clinical development program.

31 Oct 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

Researchers shed light on inner workings of endocycle

An international team of researchers led by investigators in the U.S. and Germany has shed light on the inner workings of the endocycle, a common cell cycle that fuels growth in plants, animals and some human tissues and is responsible for generating up to half of the Earth's biomass.

31 Oct 2011

New library for development of targeted cancer drugs

In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.

31 Oct 2011

Python heart holds surprises that could be of use in cardiology

The expanding hearts of pythons have intrigued researchers. Leslie Leinwand - a University of Colorado at Boulder molecular biologist who studies heart disease in humans called pythons’ expanding hearts “amazing biology”. “They're not swelling up. They're building (heart) muscle,” he said.

30 Oct 2011

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

Each year, the American Thyroid Association (ATA) recognizes the outstanding research contributions of one of its members to a greater understanding of thyroid physiology or the pathophysiology of thyroid disease, with its presentation of the John B. Stanbury Pathophysiology Medal at its Annual Meeting.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

Scientists identify nicotinamidase enzyme as new drug target for Leishmaniasis

IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.

29 Oct 2011

Researchers announce new method to build important heparin drug

Robert Linhardt is working to forever change the way some of the most widely used drugs in the world are manufactured. Today, in the journal Science, he and his partner in the research, Jian Liu, have announced an important step toward making this a reality. The discovery appears in the October 28, 2011 edition of the journal Science in a paper titled "chemoenzymatic synthesis of homogeneous ultra-low molecular weight heparins."

28 Oct 2011

NCI awards UAB $2.3M brain-tumor SPORE grant

The UAB Comprehensive Cancer Center and the UAB Division of Neurosurgery have been awarded a prestigious SPORE, or Specialized Program of Research Excellence, grant from the National Cancer Institute for $2.3 million over three years to conduct research and develop new therapies to treat brain tumors.

28 Oct 2011

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

Phase 1 clinical studies of the experimental anticancer drug lenvatinib indicate that it may achieve at least a partial response in thyroid, endometrial, and renal cancers and melanoma.

28 Oct 2011

CINJ experts available to discuss risk factors of pancreatic cancer

According to the American Cancer Society, pancreatic cancer is the fifth leading cancer killer in the country, with nearly 44,000 new cases expected in 2011 and more than 37,600 deaths by year's end. In New Jersey alone, an estimated 1,100 deaths are predicted this year due to the disease. The death of Steve Jobs, who suffered from a form of pancreatic cancer, has brought increased attention to the disease in recent weeks.

28 Oct 2011

La Jolla Institute becomes 5th participant in novel stem cell research collaboration

The La Jolla Institute for Allergy & Immunology has become the fifth organization in the prestigious Sanford Consortium for Regenerative Medicine, joining colleagues from the Salk Institute for Biological Studies, The Scripps Research Institute, University of California, San Diego and the Sanford-Burnham Medical Research Institute in the first-of-its-kind multi-institutional stem cell research collaboration.

28 Oct 2011

E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia.

27 Oct 2011

Enzyme News and Research

Pupil can constrict without any input from brain

Researchers discover key enzymes that are critical for sperm function

Health risk associated with harmful substances in food may be underestimated

Peroxiredoxin enzyme holds key to ageing process

Leg muscle dysfunction related to severity of symptoms in heart failure patients

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Researchers shed light on inner workings of endocycle

New library for development of targeted cancer drugs

Python heart holds surprises that could be of use in cardiology

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

Scientists identify nicotinamidase enzyme as new drug target for Leishmaniasis

Researchers announce new method to build important heparin drug

NCI awards UAB $2.3M brain-tumor SPORE grant

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

CINJ experts available to discuss risk factors of pancreatic cancer

La Jolla Institute becomes 5th participant in novel stem cell research collaboration

E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

Biochemistry eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News